An alternative approach to the use of Chk1 inhibitors is the combination of chemo- and immune-therapy that was recently described in two different phase 2 clinical trials coupling IO with mini-hyper-CVD in patients with relapsed or refractory ALL (62), or in older patients with newly diagnosed ALL (63). Here, CHEK1 is linked to acute lymphoblastic leukemia.